We are happy to extend a warm “EmerGence welcome” to our newest client, Prosper Animal Health. Welcome to Canada’s bioscience incubation program!
Prosper Animal Health (PAH) is an animal health company that is creating and commercializing a portfolio of breakthrough vaccines for multiple livestock and companion animal species.
Prosper controls an internationally patented breakthrough technology – IMT504 – that is designed to improve the effectiveness, diversity, safety, and duration of vaccines.
IMT504 is a novel, first-in-class oligodeoxynucleotide (ODN) which has desirable immunostimulatory effects.
IMT504 is the prototype member of the family of non-CpG motif-containing ODNs with the generic formula PyNTTTTGT. Read more about IMT504 here!
Prosper Animal Health has initially targeted four diseases which seriously impact the animal health industry worldwide:
Canine (Dog) Influenza (Flu) Vaccine
Swine Influenza (FLU) Vaccine
Porcine Reproductive & Respiratory Syndrome (Swine PRRS) Vaccine
Johne’s (Cattle) Disease Vaccine.
PAH’s management team and its scientific advisors have acclaimed global research and clinical expertise in vaccines and infectious diseases, pharmaceutical drug development, regulatory compliance, and global pharmaceutical P&L and commercial expertise. The company’s principals have held senior level positions at leading international pharmaceutical companies over the past 30 years.
Other members of the operational and advisory teams include entrepreneurs, operational specialists, scientists, and industry experts in human and animal drug development and commercialization.